US Drug Enforcement Administration (DEA) on Wednesday set new cannabis extract laws by amending the Schedule I Controlled Substances Act to include tighter regulations for marijuana extracts, including cannabidiol (CBD).
In the new drug code named "Establishment of a New Drug Code for Marihuana Extract," the DEA says it is "creating a separate code number for marihuana extract with the following definition: 'Meaning an extract containing one or more cannabinoids that has been derived from any plant of the genus Cannabis, other than the separated resin (whether crude or purified) obtained from the plant.' Extracts of marihuana will continue to be treated as Schedule I controlled substances."
This means CBD and all other extracts derived from the cannabis plant (psychoactive or not) will come under Schedule 1 drugs, like heroin, LSD, marijuana, and ecstasy, and cannot cross state lines.
Any person currently licensed to produce and handle marijuana extracts is required to apply for a modification of their registration by Jan. 13, 2017, according to the new document.
"For practical purposes, all extracts that contain CBD will also contain at least small amounts of other cannabinoids. However, if it were possible to produce from the cannabis plant an extract that contained only CBD and no other cannabinoids, such an extract would fall within the new drug code," the DEA added.
The document said, "Under international drug control treaties administered by the United Nations, some differences exist between the regulatory controls pertaining to marihuana extract versus those for marihuana and tetrahydrocannabinols."
"The DEA has previously established separate code numbers for marihuana and for tetrahydrocannabinols, but not for marihuana extract," the document's summary read.
On the other hand, medicinal marijuana activists are questioning the legality of the move.